Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1257)	6/26/2000 12:10:00 AM
From: .Trev	Respond to of 52153

Peter Thanks for your voluntary, and generous response. Just wanted to hear what the more qualified and experienced members thought about that one. You told me tons. At the end of the day I make up my own mind, but having seen the spam you mention I became suspicious. It's a pleasure reading what you guys have to post, particularly when you demonstrate generosity to the rest of us. Not all threadsters are so open minded. Cheers Trev

To: Biomaven who wrote (1257)	6/26/2000 2:00:00 AM
From: Doc Bones	Read Replies (1) \| Respond to of 52153

Stumbled upon this WSJ article from the aftermath of the "Genes Want to be Free" statement, when the good old days turned to the bad old days. I don't think this angle was discussed here. WSJ p. A8, Wed, Mar 15, 2000 <snip> "Some speculated about a link between the timing of the Clinton-Blair statement on genetic data and the White House's plan to include drug benefits in coverage of Medicare patients. The drug industry, long opposed to the Medicare plan because of price-control fears, may have sought White House support on gene data access, since gene data are critical to drug discovery, and restriction could drive up the cost of research ... these people said. "'These genomics companies have a lot of power, and the drug companies might be reacting to it,' Mr. Casdin, the investment manager said. 'They want to pay reasonable royalties and not get locked out of the game. So I suspect they are fanning some of the flames.' Dr. [Francis] Collins, however, described this view as 'fanciful'." ["Jeffrey Casdin, an investment manager at Casdin Life Science Partners"] <snip> So... did the pharmas make the deal, which caused the statement, which tanked the genomics cos., which dragged down the sector, which led the Nasdaq into a tailspin? Seems quite plausible to me, but it is mainly anonymous sources, and it could also be a plant by insiders, or news people, with their own agenda. Doc